MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Adaptive Biotechnologies Corporation (NASDAQ: ADPT), formerly, Adaptive TCR*
Organization & Developments: Adaptive Biotechnologies
Parents
Adaptive Biotechnologies Corporation (NASDAQ: ADPT), formerly, Adaptive TCR*
Children
*Adaptive TCR Corporation's platform technology focuses on the field of genomics immunology.
*Arnold Levine of the Institute for Advanced Study in Princeton, NJ, and Gerald Nepom, the director of the Benaroya Research Institute in Seattle, have joined the scientific advisory board
*Industry: Medical Devices & Equipment Sub-Industry: N/A
*Nobel laureate Andrew Fire of Stanford University has been using the technology for experiments supported by the Juvenile Diabetes Research Foundation.
*Provides vividly detailed profiles of how an individual’s immune system adapts on a genetic level to pathogens, and which can monitor exposure to drugs and vaccines
*Spun out from the Fred Hutchinson Cancer Research Center with $4.5 million in angel financing (2010)
*T-cell profiling service to researchers
*T-cell receptor profiling using Adaptive's technology and software allows scientists to study the adaptive immune system to an unprecedented depth via high-throughput T-Cell Receptor (TCR) sequencing.
*The startup’s customer roster includes researchers at Houston, TX-based MD Anderson Cancer Center, Stanford University, Yale University, Harvard University, UCLA, Baylor College of Medicine, and Washington University in St. Louis
*Three locations
2010: Adaptive TCR Seeks to Dominate New Industry in Profiling The Immune System (2010)
2019: Sequencing Firm Adaptive's $300M IPO Comes With Pharma Ambitions
2020: How Adaptive Biotechnologies and Microsoft are working to 'decode' our immune response to COVID-19
2022: Adaptive Biotechnologies (ADPT) Investor presntation - Slideshow_ seekingalpha.com
2022: Adaptive Biotechnologies Corporation 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Adaptive Biotechnologies Isn't Quite Your Portfolio's Immune Booster_ seekingalpha.com
2022: Adaptive Biotechnologies lays off 12% of workforce to narrow immunosequencing tech
2022: Adaptive Biotechnologies: A Company In Transition_ seekingalpha.com
2023: Adaptive Biotechnologies: MRD Success In A Challenging Market_ seekingalpha.com
2024: Adaptive Biotechnologies Corporation 2023 Q4 - Results - Earnings Call Presentation
2024: Adaptive Biotechnologies Receives Expanded Medicare
2024: Adaptive Biotechnologies: A Post Earnings Assessment
2024: Adaptive Biotechnologies: Making Some Progress_ seekingalpha.com
2025: Genentech Walks Away From $2B Partnership With Adaptive Biotechnologies
Digital Biotechnologies Inc.
Jumps
*Key People: Adaptive Biotechnologies
Finance & Acquisitions: Adaptive Biotechnologies